ArticleTransplantation and cellular therapy2026
Desmosine as a Novel Biomarker Candidate for Pulmonary and Cutaneous Chronic Graft-Versus-Host Disease.
Article in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Pulmonary and cutaneous fibrotic manifestations are common in chronic graft-versus-host disease (cGVHD) and can significantly reduce patients' quality of life and functional status. Plasma desmosine (pDES), a byproduct of elastin breakdown, may serve as a biomarker for fibrotic tissue involvement in cGVHD. The primmary objective was to evaluate the association between plasma desmosine levels and pulmonary and cutaneous manifestations in patients with cGVHD. We measured pDES levels in 81 cGVHD patients enrolled in the NIH cGVHD Natural History Study using liquid chromatography-tandem mass spectrometry. Patients were evaluated for bronchiolitis obliterans syndrome (BOS) according to NIH consensus criteria, lung involvement using FEV1-based NIH lung cGVHD scores, and skin sclerosis as defined by NIH skin feature scores. Statistical analyses included logistic and linear regression, adjusted for relevant covariates. The median pDES level was 0.39 ng/mL, with 77% of patients exceeding the upper limit of normal (0.280 ng/mL). No significant association was observed between pDES levels and BOS diagnosis (odds ratio [OR]: 1.15, 95% confidence interval [CI]: 0.89-1.52, P = .31). Among patients with skin sclerosis, 84% had elevated pDES levels compared with 67% of those without sclerosis. Similarly, 82% of patients with impaired lung function had elevated pDES levels versus 56% of those with normal lung function. On multivariate analysis, each 0.1 ng/mL increase in pDES was associated with a twofold increase in the odds of impaired lung function (OR: 1.96, 95% CI: 1.13-3.91; P = .032) and higher odds of skin sclerosis (OR: 1.36, 95% CI 1.02-1.92; P = .048). Elevated pDES levels were significantly associated with pulmonary function impairment and skin sclerosis in cGVHD, supporting the potential role of desmosine as a biomarker of organ involvement. Although these findings should be interpreted cautiously, they provide a strong rationale for evaluation in larger, prospective cohorts. Future studies are warranted to validate these observations and to clarify the potential utility of pDES as a prognostic biomarker, as well as its role in monitoring disease progression and treatment response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.